According to Reuters, the U.S. Attorney's Office for the Southern District of New York is investigating links between drugmakers and companies that manage prescription benefits. In at least one instance, the U.S. Attorney is investigating contracts with, services from and payments made to PBMs in connection with certain drugs.

The article notes that "when drugs are knocked off [PBMs'] formularies, patients may have to pay full price for them" and that "PBMs often keep or dump a product depending on whether they can obtain favorable pricing" from the drugmaker. 

Read the Article Here